Categories: News

SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary

BOSTON and LAUSANNE, Switzerland, June 15, 2022 /PRNewswire/ — SOPHiA GENETICS SA (Nasdaq: SOPH) (“the Company”), today announced that the Company has published its first Environmental, Social and Governance Impact Summary (“ESG Impact Summary”). The ESG Impact Summary highlights the Company’s policies, ongoing practices, and recent initiatives across a range of areas including innovation and access, protecting patient data, empowering its people, as well as other key priority areas. The ESG Impact Summary is available on SOPHiAGENETICS.COM, in the Investor Relations section.

“We are thrilled to be taking the first steps in SOPHiA GENETICS’ ESG journey. We place patient care at the heart of all our decisions. Our success is deeply rooted in our core values and the positive impact we have in the ESG areas across all levels of the organization. This is critical to our mission of creating a wiser and more sustainable healthcare system,” said Dr. Jurgi Camblong, Co-Founder and CEO at SOPHiA GENETICS.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-publishes-environmental-social-and-governance-impact-summary-301568678.html

SOURCE SOPHiA GENETICS

Staff

Recent Posts

Unique Treatment for BPH, Chronic Prostatitis, Back Pain and Kidney Stones Was Unveiled at Arab Health 2024 by Ariana Adjani

* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen's Devices were showcased at…

21 hours ago

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…

2 days ago

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

2 days ago

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…

2 days ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

2 days ago

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…

2 days ago